Edition:
United States

aTyr Pharma Inc (LIFE.OQ)

LIFE.OQ on NASDAQ Stock Exchange Global Select Market

2.75USD
16 Aug 2017
Change (% chg)

$-0.15 (-5.17%)
Prev Close
$2.90
Open
$2.85
Day's High
$2.85
Day's Low
$2.72
Volume
9,958
Avg. Vol
4,044
52-wk High
$4.45
52-wk Low
$2.12

LIFE.OQ

Chart for LIFE.OQ

About

aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based... (more)

Overall

Beta: --
Market Cap(Mil.): $69.13
Shares Outstanding(Mil.): 23.84
Dividend: --
Yield (%): --

Financials

  LIFE.OQ Industry Sector
P/E (TTM): -- 79.21 32.38
EPS (TTM): -2.19 -- --
ROI: -75.04 3.63 14.90
ROE: -82.03 5.49 16.15

BRIEF-Atyr Pharma qtrly ‍net loss per share $0.51​

* Atyr Pharma announces second quarter 2017 operating results and provides an update on innovative immunology pipeline

Aug 14 2017

BRIEF-ATyr pharma enters into first amendment to loan and security agreement

* ATyr Pharma says on june 30, entered into first amendment to loan and security agreement with silicon valley bank and solar capital ltd - SEC filing

Jul 05 2017

BRIEF-aTyr Pharma announces qtrly net loss per share, basic and diluted $0.56

* aTyr Pharma Inc - Qtrly net loss per share, basic and diluted $0.56

May 11 2017

BRIEF-Atyr Pharma announces promising top-line results from Resolaris

* Atyr Pharma announces promising top-line results from Resolaris phase 1B/2 clinical trial in patients with early onset facioscapulohumeral muscular dystrophy

Apr 24 2017

BRIEF-aTyr Pharma appoints of Timothy P. Coughlin to its board

* aTyr Pharma announces appointment of TIMOTHY P. COUGHLIN to its board of directors Source text for Eikon: Further company coverage:

Apr 10 2017

BRIEF-aTyr Pharma qtrly net loss per share attributable to common stockholders $0.53

* Atyr pharma -continues to expect that its cash, cash equivalents and investments will be sufficient to fund its anticipated operations into q3 of 2018

Mar 16 2017

BRIEF-Atyr Pharma reports issuance of U.S. patent that extends patent protection of physiocrines

* Atyr Pharma announces issuance of U.S. patent that extends patent protection of physiocrines derived from 20 out of 20 human TRNA synthetases Source text for Eikon: Further company coverage:

Mar 15 2017

BRIEF-Atyr Pharma receives EMA orphan drug designation for the treatment of limb girdle muscular dystrophy with resolaris

* Atyr Pharma receives ema orphan drug designation for the treatment of limb girdle muscular dystrophy with resolaris™ Source text for Eikon: Further company coverage:

Mar 03 2017

BRIEF-Atyr Pharma receives U.S. FDA orphan drug designation for the treatment of limb girdle muscular dystrophy with Resolaris

* Atyr Pharma Receives U.S. FDA orphan drug designation for the treatment of limb girdle muscular dystrophy with Resolaris™ Source text for Eikon: Further company coverage:

Feb 28 2017

Earnings vs. Estimates